Digital Pathology Market Size, Share & Trends by Product, Type, Application, End User - Global Forecast to 2029

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 YEARS CONSIDERED
  • 1.3.3 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH APPROACH
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key industry insights
• 2.2 RESEARCH METHODOLOGY DESIGN
• 2.3 MARKET SIZE ESTIMATION
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 MARKET ASSUMPTIONS
  • 2.6.1 OVERALL STUDY ASSUMPTIONS
• 2.7 RISK ASSESSMENT
• 2.8 RESEARCH LIMITATIONS
  • 2.8.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.8.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 DIGITAL PATHOLOGY MARKET OVERVIEW
• 4.2 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER & COUNTRY (2023)
• 4.3 DIGITAL PATHOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 DIGITAL PATHOLOGY MARKET: REGIONAL MIX

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising incidence of cancer and chronic diseases
    • 5.2.1.2 Increasing adoption of digital pathology solutions to enhance lab efficiency
    • 5.2.1.3 Growing applications in drug development and companion diagnostics
    • 5.2.1.4 Rising awareness of early cancer diagnosis in emerging markets
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of digital pathology systems
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Introduction of affordable scanners for private pathology practices
    • 5.2.3.2 Growing preference for personalized medicine
    • 5.2.3.3 High growth potential of emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Shortage of skilled pathologists
• 5.3 INDUSTRY TRENDS
  • 5.3.1 TELEPATHOLOGY
  • 5.3.2 MULTIPLEXING
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 AI in digital pathology
    • 5.4.1.2 Label-free imaging in digital pathology
    • 5.4.1.3 Computational image analysis in digital pathology
  • 5.4.2 ADJACENT TECHNOLOGIES
    • 5.4.2.1 Genomic sequencing
  • 5.4.3 COMPLEMENTARY TECHNOLOGIES
    • 5.4.3.1 Molecular imaging
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE TREND, BY REGION
  • 5.5.2 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 PORTER'S FIVE FORCES ANALYSIS
  • 5.8.1 THREAT OF NEW ENTRANTS
  • 5.8.2 THREAT OF SUBSTITUTES
  • 5.8.3 BARGAINING POWER OF SUPPLIERS
  • 5.8.4 BARGAINING POWER OF BUYERS
  • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.9 REGULATORY LANDSCAPE
  • 5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.9.2 REGULATORY ANALYSIS
    • 5.9.2.1 North America
      • 5.9.2.1.1 US
      • 5.9.2.1.2 Canada
    • 5.9.2.2 Europe
    • 5.9.2.3 Asia Pacific
      • 5.9.2.3.1 Japan
      • 5.9.2.3.2 China
      • 5.9.2.3.3 India
• 5.10 HS CODES FOR DIGITAL PATHOLOGY SCANNERS
• 5.11 PATENT ANALYSIS
  • 5.11.1 PATENT PUBLICATION TRENDS
  • 5.11.2 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR DIGITAL PATHOLOGY PATENTS
  • 5.11.3 MAJOR PATENTS
• 5.12 CASE STUDY ANALYSIS
• 5.13 KEY CONFERENCES & EVENTS, 2024-2025
• 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 BUYING CRITERIA
• 5.15 END-USER ANALYSIS
  • 5.15.1 UNMET NEEDS
  • 5.15.2 END-USER EXPECTATIONS
• 5.16 BUSINESS MODEL ANALYSIS
• 5.17 INVESTMENT & FUNDING SCENARIO
• 5.18 IMPACT OF GENERATIVE AI ON DIGITAL PATHOLOGY MARKET
  • 5.18.1 TOP USE CASES & MARKET POTENTIAL
    • 5.18.1.1 Key Use Cases
  • 5.18.2 CASE STUDIES OF GENERATIVE AI IMPLEMENTATION
    • 5.18.2.1 Case Study 1: Healthcare - Enhancing Medical Imaging
    • 5.18.2.2 Case study 2: Combining generative AI with biosensors and lab-on-a-chip technology
    • 5.18.2.3 Case study 3: Impact of Gen AI-based Digital pathology: the Korean experience
    • 5.18.2.4 AI in pathology market
    • 5.18.2.5 Tissue diagnostics market
    • 5.18.2.6 Anatomic pathology market
  • 5.18.3 USER READINESS AND IMPACT ASSESSMENT
    • 5.18.3.1 User readiness
      • 5.18.3.1.1 Pharmaceutical & biotechnology companies
      • 5.18.3.1.2 Hospitals & reference laboratories
      • 5.18.3.1.3 Academic & research institutes
    • 5.18.3.2 Impact assessment
      • 5.18.3.2.1 Pharmaceutical & biotechnology companies
      • 5.18.3.2.2 Hospitals & reference laboratories
      • 5.18.3.2.3 Academic & research institutes

6 DIGITAL PATHOLOGY MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 SCANNERS
  • 6.2.1 BRIGHTFIELD SCANNERS
    • 6.2.1.1 Cost-efficient features to boost demand
  • 6.2.2 FLUORESCENCE SCANNERS
    • 6.2.2.1 Ability to detect cellular structures and biomarkers to fuel uptake
  • 6.2.3 OTHER SCANNERS
• 6.3 SOFTWARE, BY TYPE
  • 6.3.1 INTEGRATED SOFTWARE
    • 6.3.1.1 Single & effective suite for multiple applications to propel market
  • 6.3.2 STANDALONE SOFTWARE
    • 6.3.2.1 Information management software
      • 6.3.2.1.1 Management of image repositories to fuel uptake
    • 6.3.2.2 Image analysis software
      • 6.3.2.2.1 Ability to automate quantitative evaluation to support market growth
• 6.4 SOFTWARE, BY DEPLOYMENT MODEL
  • 6.4.1 CLOUD-BASED MODEL
    • 6.4.1.1 Benefits of cloud-based models and ease of access to drive market
  • 6.4.2 ON-PREMISE MODEL
    • 6.4.2.1 High data security and integration with HCIT solutions to fuel uptake
  • 6.4.3 HYBRID MODEL
    • 6.4.3.1 Combined flexibility to support market growth
• 6.5 STORAGE SYSTEMS
  • 6.5.1 GROWING FOCUS ON STORAGE OF HIGH-RESOLUTION IMAGES TO DRIVE MARKET

7 DIGITAL PATHOLOGY MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 HUMAN PATHOLOGY
  • 7.2.1 INCREASING CANCER RESEARCH ACTIVITIES TO PROPEL MARKET
• 7.3 VETERINARY PATHOLOGY
  • 7.3.1 IMPROVEMENTS IN ANIMAL DISEASE DIAGNOSTICS TO SUPPORT MARKET GROWTH

8 DIGITAL PATHOLOGY MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 DRUG DISCOVERY
  • 8.2.1 INCREASING FOCUS ON LIFE SCIENCES R&D TO DRIVE MARKET
• 8.3 DISEASE DIAGNOSIS
  • 8.3.1 INTEGRATION OF AI & ML IN COMPLEX DIAGNOSTICS TO BOOST DEMAND
• 8.4 TRAINING & EDUCATION
  • 8.4.1 ABILITY TO PROVIDE REAL-TIME LEARNING EXPERIENCES TO SUPPORT MARKET GROWTH

9 DIGITAL PATHOLOGY MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 9.2.1 INCREASING FOCUS ON DRUG TOXICOLOGY TESTING AND RISING NUMBER OF PRECLINICAL TRIALS TO PROPEL MARKET
• 9.3 HOSPITALS AND REFERENCE LABORATORIES
  • 9.3.1 HIGH INCIDENCE OF INFECTIOUS DISEASES TO BOOST DEMAND
• 9.4 ACADEMIC & RESEARCH INSTITUTES
  • 9.4.1 INCREASING PUBLIC & PRIVATE FUNDING INVESTMENTS TO SUPPORT MARKET GROWTH

10 DIGITAL PATHOLOGY MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 US
    • 10.2.1.1 Favorable reimbursements for diagnostics to drive market
  • 10.2.2 CANADA
    • 10.2.2.1 Growing awareness of early cancer detection & diagnosis to drive market
• 10.3 EUROPE
  • 10.3.1 GERMANY
    • 10.3.1.1 High healthcare expenditure and supportive research initiatives to drive market
  • 10.3.2 UK
    • 10.3.2.1 Government funding investments for pathology services to fuel market
  • 10.3.3 SWEDEN
    • 10.3.3.1 Increasing prevalence of chronic diseases to support market growth
  • 10.3.4 DENMARK
    • 10.3.4.1 Increasing deployment of digital pathology solutions to support market growth
  • 10.3.5 FRANCE
    • 10.3.5.1 Increasing government funding and favorable insurance system to drive adoption
  • 10.3.6 SPAIN
    • 10.3.6.1 Supportive collaborations among leading companies and hospitals to boost demand
  • 10.3.7 ITALY
    • 10.3.7.1 Integration of AI & ML to support market growth
  • 10.3.8 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 CHINA
    • 10.4.1.1 Increasing establishment of hospitals and reference laboratories to drive market
  • 10.4.2 JAPAN
    • 10.4.2.1 Advanced healthcare infrastructure to support market growth
  • 10.4.3 INDIA
    • 10.4.3.1 Growth in pharmaceutical industry to propel market
  • 10.4.4 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 BRAZIL
    • 10.5.1.1 High adoption of POC testing to drive market
  • 10.5.2 MEXICO
    • 10.5.2.1 Growth in companion diagnostics to fuel uptake
  • 10.5.3 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
  • 10.6.2 GCC COUNTRIES
  • 10.6.3 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN DIGITAL PATHOLOGY MARKET
• 11.3 REVENUE ANALYSIS
• 11.4 MARKET SHARE ANALYSIS
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.5.5.1 Product footprint
    • 11.5.5.2 Application footprint
    • 11.5.5.3 End-user footprint
    • 11.5.5.4 Region footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 11.7 VALUATION & FINANCIAL METRICS
• 11.8 BRAND/SOFTWARE COMPARATIVE ANALYSIS
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS
  • 11.9.2 DEALS
  • 11.9.3 OTHER DEVELOPMENTS

12 COMPANY PROFILES

• 12.1 KEY COMPANIES
  • 12.1.1 DANAHER CORPORATION
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Product enhancements
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Key strengths
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses and competitive threats
  • 12.1.2 KONINKLIJKE PHILIPS N.V.
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Product launches
      • 12.1.2.3.2 Deals
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Key strengths
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses and competitive threats
  • 12.1.3 HAMAMATSU PHOTONICS K.K.
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Product approvals
      • 12.1.3.3.2 Deals
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses and competitive threats
  • 12.1.4 F. HOFFMANN-LA ROCHE LTD.
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product Launches & approvals
      • 12.1.4.3.2 Deals
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Key strengths
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses and competitive threats
  • 12.1.5 SECTRA AB
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Deals
      • 12.1.5.3.2 Other developments
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Key strengths
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses and competitive threats
  • 12.1.6 AKOYA BIOSCIENCES, INC.
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Product Launches & approvals
      • 12.1.6.3.2 Deals
  • 12.1.7 FUJIFILM HOLDINGS CORPORATION
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Deals
  • 12.1.8 HOLOGIC, INC.
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Product approvals
  • 12.1.9 3DHISTECH LTD.
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Product launches & enhancements
      • 12.1.9.3.2 Other developments
  • 12.1.10 APOLLO ENTERPRISE IMAGING CORP.
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Product enhancements
      • 12.1.10.3.2 Deals
  • 12.1.11 XIFIN, INC.
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
    • 12.1.11.3 Recent developments
      • 12.1.11.3.1 Product launches
      • 12.1.11.3.2 Deals
  • 12.1.12 HURON DIGITAL PATHOLOGY
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
    • 12.1.12.3 Recent developments
      • 12.1.12.3.1 Product approvals
      • 12.1.12.3.2 Deals
      • 12.1.12.3.3 Other developments
  • 12.1.13 CORISTA
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
    • 12.1.13.3 Recent developments
      • 12.1.13.3.1 Deals
      • 12.1.13.3.2 Other developments
  • 12.1.14 INDICA LABS
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products offered
    • 12.1.14.3 Recent developments
      • 12.1.14.3.1 Product launches & approvals
      • 12.1.14.3.2 Deals
  • 12.1.15 OBJECTIVE PATHOLOGY SERVICES
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products offered
  • 12.1.16 OPTRASCAN, INC.
    • 12.1.16.1 Business overview
    • 12.1.16.2 Products offered
    • 12.1.16.3 Recent developments
      • 12.1.16.3.1 Product launches & approvals
      • 12.1.16.3.2 Deals
  • 12.1.17 GLENCOE SOFTWARE, INC.
    • 12.1.17.1 Business overview
    • 12.1.17.2 Products offered
    • 12.1.17.3 Recent developments
      • 12.1.17.3.1 Product enhancements
  • 12.1.18 AIFORIA TECHNOLOGIES OY
    • 12.1.18.1 Business overview
    • 12.1.18.2 Products offered
    • 12.1.18.3 Recent developments
      • 12.1.18.3.1 Deals
  • 12.1.19 PAIGE AI, INC.
    • 12.1.19.1 Business overview
    • 12.1.19.2 Products offered
    • 12.1.19.3 Recent developments
      • 12.1.19.3.1 Product launches & enhancements
      • 12.1.19.3.2 Deals
  • 12.1.20 PROSCIA, INC.
    • 12.1.20.1 Business overview
    • 12.1.20.2 Products offered
    • 12.1.20.3 Recent developments
      • 12.1.20.3.1 Product enhancements & approvals
      • 12.1.20.3.2 Deals
• 12.2 OTHER PLAYERS
  • 12.2.1 PATHAI
  • 12.2.2 KONFOONG BIOTECH INTERNATIONAL CO., LTD.
  • 12.2.3 MIKROSCAN TECHNOLOGIES, INC.
  • 12.2.4 MOTIC DIGITAL PATHOLOGY
  • 12.2.5 KANTERON SYSTEMS
  • 12.2.6 MORPHLE LABS INC.

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS

List of Tables

• TABLE 1 FACTOR ANALYSIS
• TABLE 2 RISK ASSESSMENT
• TABLE 3 INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
• TABLE 4 US: GROWTH IN NUMBER OF PERSONALIZED MEDICINES (2008-2020)
• TABLE 5 NUMBER OF INHABITANTS PER PATHOLOGIST, BY COUNTRY, 2020
• TABLE 6 AVERAGE SELLING PRICE TREND OF DIGITAL PATHOLOGY PRODUCTS, BY REGION
• TABLE 7 AVERAGE SELLING PRICE OF DIGITAL PATHOLOGY PRODUCTS
• TABLE 8 DIGITAL PATHOLOGY MARKET: PORTER'S FIVE FORCES
• TABLE 9 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 10 US FDA: MEDICAL DEVICE CLASSIFICATION
• TABLE 11 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
• TABLE 12 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
• TABLE 13 EUROPE: CLASSIFICATION OF IVD DEVICES
• TABLE 14 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
• TABLE 15 CHINA: CLASSIFICATION OF MEDICAL DEVICES
• TABLE 16 HS CODE: DIGITAL PATHOLOGY SCANNER
• TABLE 17 CASE STUDY 1: ASSESSING IMAGE QUALITY FOR COMPARATIVE MULTI-ASSESSMENT EVALUATION OF APERIO GT 450 DX
• TABLE 18 CASE STUDY 2: PROMOTION OF PATHOLOGY WORKFLOW EFFICIENCY
• TABLE 19 CASE STUDY 3: INTEGRATION OF ARTIFICIAL INTELLIGENCE IN DIGITAL PATHOLOGY
• TABLE 20 DIGITAL PATHOLOGY MARKET: KEY CONFERENCES & EVENTS, 2024-2025
• TABLE 21 STAKEHOLDERS IN BUYING PROCESS: DEFINITIONS
• TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR DIGITAL PATHOLOGY, BY PRODUCT
• TABLE 23 KEY BUYING CRITERIA FOR DIGITAL PATHOLOGY PRODUCTS
• TABLE 24 UNMET NEEDS IN DIGITAL PATHOLOGY MARKET
• TABLE 25 END-USER EXPECTATIONS IN DIGITAL PATHOLOGY MARKET
• TABLE 26 DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 27 SCANNING MAGNIFICATION AND APPLICATIONS
• TABLE 28 DIGITAL PATHOLOGY SCANNERS OFFERED BY KEY MARKET PLAYERS
• TABLE 29 DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 30 DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 31 BRIGHTFIELD SCANNERS OFFERED BY KEY MARKET PLAYERS
• TABLE 32 BRIGHTFIELD SCANNERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 33 FLUORESCENCE SCANNERS OFFERED BY KEY MARKET PLAYERS
• TABLE 34 FLUORESCENCE SCANNERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 35 OTHER SCANNERS OFFERED BY KEY MARKET PLAYERS
• TABLE 36 OTHER SCANNERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 37 DIGITAL PATHOLOGY SOFTWARE OFFERED BY KEY MARKET PLAYERS
• TABLE 38 DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 39 DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 40 INTEGRATED SOFTWARE OFFERED BY KEY MARKET PLAYERS
• TABLE 41 INTEGRATED SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 42 STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 43 STANDALONE SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 44 INFORMATION MANAGEMENT SOFTWARE OFFERED BY KEY MARKET PLAYERS
• TABLE 45 INFORMATION MANAGEMENT SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 46 IMAGE ANALYSIS SOFTWARE OFFERED BY KEY MARKET PLAYERS
• TABLE 47 IMAGE ANALYSIS SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 48 DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 49 CLOUD-BASED SOFTWARE OFFERED BY KEY MARKET PLAYERS
• TABLE 50 CLOUD-BASED MODEL MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 51 ON-PREMISE SOFTWARE OFFERED BY KEY MARKET PLAYERS
• TABLE 52 ON-PREMISE MODEL MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 53 HYBRID SOFTWARE OFFERED BY KEY MARKET PLAYERS
• TABLE 54 HYBRID MODEL MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 55 STORAGE SYSTEMS OFFERED BY KEY MARKET PLAYERS
• TABLE 56 DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 57 DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 58 HUMAN DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 59 VETERINARY DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 60 DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 61 SOFTWARE IMPACT ANALYSIS, BY APPLICATION
• TABLE 62 DIGITAL PATHOLOGY APPLICATIONS IN DRUG DISCOVERY
• TABLE 63 DIGITAL PATHOLOGY MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 64 DIGITAL PATHOLOGY MARKET FOR DISEASE DIAGNOSIS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 65 DIGITAL PATHOLOGY MARKET FOR TRAINING & EDUCATION, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 66 DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 67 SOFTWARE IMPACT ANALYSIS, BY END USER
• TABLE 68 DIGITAL PATHOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 69 DEPLOYMENT OF DIGITAL PATHOLOGY SOLUTIONS IN HOSPITALS
• TABLE 70 DIGITAL PATHOLOGY MARKET FOR HOSPITALS AND REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 71 DIGITAL PATHOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 72 DIGITAL PATHOLOGY MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 73 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 74 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 75 NORTH AMERICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 76 NORTH AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 77 NORTH AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 78 NORTH AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 79 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 80 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 81 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 82 US: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
• TABLE 83 US: KEY MACROINDICATORS
• TABLE 84 US: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 85 US: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 86 US: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 87 US: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 88 US: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 89 US: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 90 US: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 91 US: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 92 CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
• TABLE 93 CANADA: FUNDING INITIATIVES FOR DIGITAL PATHOLOGY
• TABLE 94 CANADA: KEY MACROINDICATORS
• TABLE 95 CANADA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 96 CANADA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 97 CANADA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 98 CANADA: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 99 CANADA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
• TABLE 100 CANADA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 101 CANADA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 102 CANADA: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 103 EUROPE: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 104 EUROPE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 105 EUROPE: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 106 EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 107 EUROPE: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 108 EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 109 EUROPE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 110 EUROPE: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 111 EUROPE: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 112 GERMANY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
• TABLE 113 GERMANY: KEY MACROINDICATORS
• TABLE 114 GERMANY: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 115 GERMANY: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 116 GERMANY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 117 GERMANY: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 118 GERMANY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
• TABLE 119 GERMANY: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 120 GERMANY: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 121 GERMANY: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 122 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
• TABLE 123 UK: KEY MACROINDICATORS
• TABLE 124 UK: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 125 UK: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 126 UK: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 127 UK: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 128 UK: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
• TABLE 129 UK: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 130 UK: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 131 UK: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 132 SWEDEN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
• TABLE 133 SWEDEN: KEY MACROINDICATORS
• TABLE 134 SWEDEN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 135 SWEDEN: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 136 SWEDEN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 137 SWEDEN: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 138 SWEDEN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
• TABLE 139 SWEDEN: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 140 SWEDEN: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 141 SWEDEN: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 142 DENMARK: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
• TABLE 143 DENMARK: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 144 DENMARK: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 145 DENMARK: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 146 DENMARK: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 147 DENMARK: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
• TABLE 148 DENMARK: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 149 DENMARK: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 150 DENMARK: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 151 FRANCE: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
• TABLE 152 FRANCE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 153 FRANCE: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 154 FRANCE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 155 FRANCE: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 156 FRANCE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
• TABLE 157 FRANCE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 158 FRANCE: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 159 FRANCE: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 160 SPAIN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 161 SPAIN: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 162 SPAIN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 163 SPAIN: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 164 SPAIN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 165 SPAIN: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 166 SPAIN: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 167 SPAIN: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 168 ITALY: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 169 ITALY: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 170 ITALY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 171 ITALY: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 172 ITALY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
• TABLE 173 ITALY: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 174 ITALY: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 175 ITALY: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 176 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 177 REST OF EUROPE: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 178 REST OF EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 179 REST OF EUROPE: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 180 REST OF EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 181 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 182 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 183 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 184 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 185 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 186 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 187 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 188 ASIA PACIFIC: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 189 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 190 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 191 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 192 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 193 CHINA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
• TABLE 194 CHINA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 195 CHINA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 196 CHINA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 197 CHINA: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 198 CHINA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
• TABLE 199 CHINA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 200 CHINA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 201 CHINA: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 202 JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
• TABLE 203 JAPAN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 204 JAPAN: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 205 JAPAN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 206 JAPAN: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 207 JAPAN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 208 JAPAN: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 209 JAPAN: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 210 JAPAN: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 211 INDIA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
• TABLE 212 INDIA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 213 INDIA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 214 INDIA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 215 INDIA: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 216 INDIA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
• TABLE 217 INDIA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 218 INDIA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 219 INDIA: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 220 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 221 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 222 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 223 REST OF ASIA PACIFIC: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 224 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
• TABLE 225 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 226 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 227 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 228 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 229 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 230 LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 231 LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 232 LATIN AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 233 LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 234 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 235 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 236 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 237 BRAZIL: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
• TABLE 238 BRAZIL: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 239 BRAZIL: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 240 BRAZIL: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 241 BRAZIL: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 242 BRAZIL: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
• TABLE 243 BRAZIL: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 244 BRAZIL: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 245 BRAZIL: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 246 MEXICO: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
• TABLE 247 MEXICO: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 248 MEXICO: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 249 MEXICO: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 250 MEXICO: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 251 MEXICO: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 252 MEXICO: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 253 MEXICO: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 254 MEXICO: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 255 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 256 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 257 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 258 REST OF LATIN AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 259 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 260 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 261 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 262 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 263 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 264 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 265 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 266 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 267 MIDDLE EAST & AFRICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 268 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 269 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 270 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 271 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 272 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 273 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 274 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 275 GCC COUNTRIES: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 276 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
• TABLE 277 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 278 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 279 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 280 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 281 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 282 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 283 REST OF MIDDLE EAST & AFRICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 284 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 285 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 286 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 287 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 288 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES
• TABLE 289 DIGITAL PATHOLOGY MARKET: DEGREE OF COMPETITION
• TABLE 290 DIGITAL PATHOLOGY MARKET: PRODUCT FOOTPRINT
• TABLE 291 DIGITAL PATHOLOGY MARKET: APPLICATION FOOTPRINT
• TABLE 292 DIGITAL PATHOLOGY MARKET: END-USER FOOTPRINT
• TABLE 293 DIGITAL PATHOLOGY MARKET: REGION FOOTPRINT
• TABLE 294 DIGITAL PATHOLOGY MARKET: DETAILED LIST OF KEY START-UPS/SMES
• TABLE 295 DIGITAL PATHOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
• TABLE 296 DIGITAL PATHOLOGY MARKET: PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2021-MARCH 2024
• TABLE 297 DIGITAL PATHOLOGY MARKET: DIGITAL PATHOLOGY MARKET: DEALS, JANUARY 2021-MARCH 2024
• TABLE 298 DIGITAL PATHOLOGY MARKET: OTHER DEVELOPMENTS, JANUARY 2021-MARCH 2024
• TABLE 299 DANAHER CORPORATION: COMPANY OVERVIEW
• TABLE 300 DANAHER CORPORATION: PRODUCTS OFFERED
• TABLE 301 DANAHER CORPORATION: PRODUCT ENHANCEMENTS, JANUARY 2021-JUNE 2024
• TABLE 302 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
• TABLE 303 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED
• TABLE 304 KONINKLIJKE PHILIPS N.V: PRODUCT LAUNCHES, JANUARY 2021-JUNE 2024
• TABLE 305 KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2021-JUNE 2024
• TABLE 306 HAMAMATSU PHOTONICS K.K.: COMPANY OVERVIEW
• TABLE 307 HAMAMATSU PHOTONICS K.K.: PRODUCTS OFFERED
• TABLE 308 HAMAMATSU PHOTONICS K.K.: PRODUCT APPROVALS, JANUARY 2021-JUNE 2024
• TABLE 309 HAMAMATSU PHOTONICS K.K.: DEALS, JANUARY 2021-JUNE 2024
• TABLE 310 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
• TABLE 311 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
• TABLE 312 HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2024
• TABLE 313 HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021-JUNE 2024
• TABLE 314 SECTRA AB: COMPANY OVERVIEW
• TABLE 315 SECTRA AB: PRODUCTS OFFERED
• TABLE 316 SECTRA AB: DEALS, JANUARY 2021-JUNE 2024
• TABLE 317 SECTRA AB: OTHER DEVELOPMENTS, JANUARY 2021-JUNE 2024
• TABLE 318 AKOYA BIOSCIENCES, INC.: COMPANY OVERVIEW
• TABLE 319 AKOYA BIOSCIENCES, INC.: PRODUCTS OFFERED
• TABLE 320 AKOYA BIOSCIENCES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2024
• TABLE 321 AKOYA BIOSCIENCES, INC.: DEALS, JANUARY 2021-JUNE 2024
• TABLE 322 FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW
• TABLE 323 FUJIFILM HOLDINGS CORPORATION: PRODUCTS OFFERED
• TABLE 324 FUJIFILM HOLDINGS CORPORATION: DEALS, JANUARY 2021-JUNE 2024
• TABLE 325 HOLOGIC, INC: COMPANY OVERVIEW
• TABLE 326 HOLOGIC, INC: PRODUCTS OFFERED
• TABLE 327 HOLOGIC, INC: PRODUCT APPROVALS, JANUARY 2021-JUNE 2024
• TABLE 328 3DHISTECH LTD.: COMPANY OVERVIEW
• TABLE 329 3DHISTECH LTD.: PRODUCTS OFFERED
• TABLE 330 3DHISTECH LTD.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021-JUNE 2024
• TABLE 331 3DHISTECH LTD.: OTHER DEVELOPMENTS, JANUARY 2021-JUNE 2024
• TABLE 332 APOLLO ENTERPRISE IMAGING CORP.: COMPANY OVERVIEW
• TABLE 333 APOLLO ENTERPRISE IMAGING CORP.: PRODUCTS OFFERED
• TABLE 334 APOLLO ENTERPRISE IMAGING CORP.: PRODUCT ENHANCEMENTS, JANUARY 2021-JUNE 2024
• TABLE 335 APOLLO ENTERPRISE IMAGING CORP.: DEALS, JANUARY 2021-JUNE 2024
• TABLE 336 XIFIN, INC.: COMPANY OVERVIEW
• TABLE 337 XIFIN, INC.: PRODUCTS OFFERED
• TABLE 338 XIFIN, INC.: PRODUCT LAUNCHES, JANUARY 2021-JUNE 2024
• TABLE 339 XIFIN, INC.: DEALS, JANUARY 2021-JUNE 2024
• TABLE 340 HURON DIGITAL PATHOLOGY: COMPANY OVERVIEW
• TABLE 341 HURON DIGITAL PATHOLOGY: PRODUCTS OFFERED
• TABLE 342 HURON DIGITAL PATHOLOGY: PRODUCT APPROVALS, JANUARY 2021-JUNE 2024
• TABLE 343 HURON DIGITAL PATHOLOGY: DEALS, JANUARY 2021-JUNE 2024
• TABLE 344 HURON DIGITAL PATHOLOGY: OTHER DEVELOPMENTS, JANUARY 2021-JUNE 2024
• TABLE 345 CORISTA: COMPANY OVERVIEW
• TABLE 346 CORISTA: PRODUCTS OFFERED
• TABLE 347 CORISTA: DEALS, JANUARY 2021-JUNE 2024
• TABLE 348 CORISTA: OTHER DEVELOPMENTS, JANUARY 2021-JUNE 2024
• TABLE 349 INDICA LABS: COMPANY OVERVIEW
• TABLE 350 INDICA LABS: PRODUCTS OFFERED
• TABLE 351 INDICA LABS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2024
• TABLE 352 INDICA LABS: DEALS, JANUARY 2021-JUNE 2024
• TABLE 353 OBJECTIVE PATHOLOGY SERVICES: COMPANY OVERVIEW
• TABLE 354 OBJECTIVE PATHOLOGY SERVICES: PRODUCTS OFFERED
• TABLE 355 OPTRASCAN, INC.: COMPANY OVERVIEW
• TABLE 356 OPTRASCAN, INC.: PRODUCTS OFFERED
• TABLE 357 OPTRASCAN, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2024
• TABLE 358 OPTRASCAN, INC.: DEALS, JANUARY 2021-JUNE 2024
• TABLE 359 GLENCOE SOFTWARE, INC.: COMPANY OVERVIEW
• TABLE 360 GLENCOE SOFTWARE, INC.: PRODUCTS OFFERED
• TABLE 361 GLENCOE SOFTWARE, INC.: PRODUCT ENHANCEMENTS, JANUARY 2021-JUNE 2024
• TABLE 362 AIFORIA TECHNOLOGIES OY: COMPANY OVERVIEW
• TABLE 363 AIFORIA TECHNOLOGIES OY: PRODUCTS OFFERED
• TABLE 364 AIFORIA TECHNOLOGIES OY: DEALS, JANUARY 2021-JUNE 2024
• TABLE 365 PAIGE AI, INC.: COMPANY OVERVIEW
• TABLE 366 PAIGE AI, INC.: PRODUCTS OFFERED
• TABLE 367 PAIGE AI, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021-JUNE 2024
• TABLE 368 PAIGE AI, INC.: DEALS, JANUARY 2021-JUNE 2024
• TABLE 369 PROSCIA, INC.: COMPANY OVERVIEW
• TABLE 370 PROSCIA, INC.: PRODUCTS OFFERED
• TABLE 371 PROSCIA, INC.: PRODUCT ENHANCEMENTS & APPROVALS, JANUARY 2021-JUNE 2024
• TABLE 372 PROSCIA, INC.: DEALS, JANUARY 2021-JUNE 2024

List of Figures

• FIGURE 1 DIGITAL PATHOLOGY MARKET
• FIGURE 2 RESEARCH DESIGN
• FIGURE 3 PRIMARY SOURCES
• FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY DEMAND SIDE, SUPPLY SIDE, DESIGNATION, AND REGION
• FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
• FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
• FIGURE 7 DIGITAL PATHOLOGY MARKET: REVENUE SHARE ANALYSIS ILLUSTRATION OF DANAHER CORPORATION
• FIGURE 8 BOTTOM-UP APPROACH
• FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
• FIGURE 10 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN DIGITAL PATHOLOGY MARKET (2024-2029)
• FIGURE 11 DATA TRIANGULATION METHODOLOGY
• FIGURE 12 DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
• FIGURE 13 DIGITAL PATHOLOGY MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
• FIGURE 14 DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
• FIGURE 15 DIGITAL PATHOLOGY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
• FIGURE 16 GEOGRAPHIC SNAPSHOT OF DIGITAL PATHOLOGY MARKET
• FIGURE 17 RISING INCIDENCE OF CANCER AND GROWING ADOPTION OF PATHOLOGY SOLUTIONS FOR ENHANCED LAB EFFICIENCY TO DRIVE MARKET
• FIGURE 18 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
• FIGURE 19 UK TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
• FIGURE 20 ASIA PACIFIC SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 21 DIGITAL PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 22 GLOBAL CANCER INCIDENCE, 2008-2030
• FIGURE 23 FDA-APPROVED PERSONALIZED MEDICINES, 2015-2021
• FIGURE 24 DIGITAL PATHOLOGY MARKET: VALUE CHAIN ANALYSIS
• FIGURE 25 DIGITAL PATHOLOGY MARKET: ECOSYSTEM ANALYSIS
• FIGURE 26 DIGITAL PATHOLOGY MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 27 EUROPE: IVDR TIMELINE
• FIGURE 28 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR DIGITAL PATHOLOGY PATENTS, 2013-2023
• FIGURE 29 MAJOR PATENTS FOR DIGITAL PATHOLOGY (2013-2023)
• FIGURE 30 KEY BUYING CRITERIA FOR DIGITAL PATHOLOGY PRODUCTS
• FIGURE 32 MARKET POTENTIAL OF GENERATIVE AI IN ENHANCING DIGITAL PATHOLOGY ACROSS INDUSTRIES
• FIGURE 33 IMPACT OF GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
• FIGURE 34 NORTH AMERICA: DIGITAL PATHOLOGY MARKET SNAPSHOT
• FIGURE 35 EUROPE: DIGITAL PATHOLOGY MARKET SNAPSHOT
• FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN DIGITAL PATHOLOGY MARKET
• FIGURE 37 DIGITAL PATHOLOGY MARKET: MARKET SHARE ANALYSIS (2023)
• FIGURE 38 DIGITAL PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
• FIGURE 39 DIGITAL PATHOLOGY MARKET: COMPANY FOOTPRINT
• FIGURE 40 DIGITAL PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
• FIGURE 41 EV/EBITDA OF KEY VENDORS
• FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF DIGITAL PATHOLOGY VENDORS
• FIGURE 43 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
• FIGURE 44 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023)
• FIGURE 45 HAMAMATSU PHOTONICS K.K.: COMPANY SNAPSHOT (2023)
• FIGURE 46 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
• FIGURE 47 SECTRA AB.: COMPANY SNAPSHOT (2023)
• FIGURE 48 AKOYA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2023)
• FIGURE 49 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)
• FIGURE 50 HOLOGIC, INC: COMPANY SNAPSHOT (2023)